Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fujifilm, Dr Reddy’s to establish JV company in Japan
The joint venture which will focus on developing, manufacturing and promoting generic drugs, will be 51% owned by Fujifilm and 49% by the Indian drug maker. The new
The joint venture which will focus on developing, manufacturing and promoting generic drugs, will be 51% owned by Fujifilm and 49% by the Indian drug maker. The new
Chasse-sur-Rhone provides for process scale-ups, the supply of clinical batches and the regular production of low volume compounds under cGMP. Freeport site performs custom manufacturing services from late
The tie up allows Ironwood to develop and commercialize the product, however Depomed will help in initial product formulation. As per the terms of the deal, Depomed is
Mylan‘s net earnings were $146.99m, compared to $86.93m for the same period in the prior year. The company has posted earnings from operations as $280.47m for the second
Genedata Expressionist for MS processes large experimental data sets of GC- and LC-MS (/MS), labeled and unlabeled – regardless of data formats. Each technology workflow requires specific pre-processing
The company has bought a 16mm and an 18mm Leistritz twin screw extruders. With this new HME, the company is now eligible to conduct feasibility studies by using
Dr Reddy’s Gemcitabine for Injection is the generic version of a cancer medication, Gemzar. Gemzar is indicated as a treatment for cancers of the pancreas, lung and breast
With this license extension application, the company is seeking marketing approval from the EMA for Zonegran as a monotherapy for patients suffering from epilepsy with partial seizures, with
The partnership allows INC to conduct research work on Debiopharm’s drug development project with the management of a clinical study. The partnership further agrees that the Debiopharm’s future
The study of two drugs which are mixed sigma-1 agonists are designed to assess their anti-amnesic and neuroprotective effects. The study includes a model to which oligomeric amyloid